OMB Veto Over NIH Grants Reshapes Biomedical Research
Meta commentary - no external expert source; basis: Feeds.arstechnica (2026-09-21). #MetaScience
A Leak That Confirmed a Larger Plan
The first public signal did not arrive as a formal announcement. It came as a leak: a report describing a tense meeting inside the White House, where the director of the National Institutes of Health, Jay Bhattacharya, tried to block a new attempt to place research funding decisions under direct political control. [1] What followed turned the fragment into a pattern.
The administration is now drafting an executive order that would give Russell Vought, the head of the Office of Management and Budget, veto power over every individual grant awarded by the NIH. [1] The move came over Bhattacharya’s objections. The leak was not about a single meeting. It was about a mechanism being built, piece by piece, in plain sight.
The NIH is the largest funder of biomedical research on the planet. Its $47 billion budget is larger than that of the next 10 research funders combined. That money flows largely through grants to academic researchers at universities. It supports everything from basic biological research to clinical trials, and it has helped the biotechnology industry flourish. A veto over every one of those grants is not a minor procedural tweak. It is a transfer of decision-making authority over the world’s largest biomedical research portfolio.
Vought’s interest in the NIH’s grantmaking did not begin with this meeting. Immediately after Trump re-entered the Oval Office, the agency terminated a broad range of grants on topics like pandemic preparedness and health disparities. It also proposed a budget that would shrink the NIH by nearly half. Congress rejected that cut. A court voided the policy behind the grant terminations. Vought responded to those setbacks by proposing new grant funding rules that would make political considerations key determinants in which grants get funded. Congress put that rule on hold, too.
From Blocking Fields to Vetoing Everything
Each of Vought’s earlier attempts shared a common feature: they targeted categories. Entire fields of research were defunded. A budget was proposed that would have cut the agency in half. A rule was drafted to inject political criteria into funding decisions. All of those approaches were broad, and all of them were blocked — by Congress, by a court, or by both. The pending executive order is different. It does not block a field. It does not shrink a budget. It places a single person’s veto over every individual grant.
The shift matters because it changes the unit of control. Blocking funding for entire fields of research is visible, contestable, and subject to legislative and judicial review. A veto over each grant is granular. It operates at the level of the individual proposal, after funding decisions have been made. Vought leveraged one of Trump’s weaknesses: a desire to harm Harvard University. Early in his second term, Trump suspended all grant funding to a number of universities, seeking large payments from them in exchange for restoring the funding and dropping investigations. In the White House meeting, Vought presented OMB control of NIH grants as an alternate means of targeting Harvard. [1] Bhattacharya objected.
That objection was not a foregone conclusion. Bhattacharya has treated his NIH post as an opportunity to right perceived wrongs, so there were plenty of reasons to think he might be equally willing to go along with Vought’s ideas.
The Peer Review System and the Question of Scale
The practical question is how a two-person committee could evaluate the volume of grants the NIH processes. As heads of their respective agencies, Vought and Bhattacharya have other duties. They would be hard-pressed to give each proposal a serious evaluation. The arithmetic alone raises the question of whether the committee is designed to review grants or to stop them.
In the past, the NIH determined funding by ordering grants based on scientific merit scores assigned by expert peer reviewers. That system provides an obvious way to shift money from rejected grants to the highest-quality unfunded proposals. But Vought has also been attempting to limit the use of peer review in evaluating grants. If peer review is curtailed and no replacement mechanism exists for reallocating funds, the NIH could find itself unable to spend its congressional appropriation. That outcome would not require a single grant to be formally rejected on political grounds. It would happen through the absence of a functioning process.
The pending executive order will almost certainly be rejected by the courts, as it clearly fits the key standard for illegal administrative actions: arbitrary and capricious. It solves no problems, it is not required by any law, and it is difficult to imagine any legal justification for it. “Vought wants to stop the NIH from spending its budget” is not a legal justification. But for the policy to reach the courts, someone will first have to prove that they are sufficiently harmed to have standing to sue. As with so many other administration actions, that means the pending executive order could do a lot of damage before the courts can intervene.
What remains open is not whether the veto power is legal. That question will be answered by judges. What remains open is whether a system built on expert peer review, processing tens of thousands of grants a year, can function at all when a two-person committee holds unanimous veto power over every one of them. The NIH has never operated that way. No major research funder has. The scalability of the model is the question the courts will not answer, because by the time they do, the grants may already have been stopped.
Sources
1. MSN (Original laut Text: Politico) — Portal copy
Mentioned organisations (context, not sources)
- National Institutes of Health — Organisation (homepage)